The transition from generic drugs to innovative drugs is beginning to show results, with Wanbond's Q1 2026 net profit expected to increase by 985.40%

On March 6th, Wanbangde (002082.SZ) announced its performance forecast for the first quarter of 2026. The net profit attributable to shareholders of the listed company for this reporting period is expected to be 165 million yuan, a 985.40% increase compared to the same period last year; net profit after deducting non-recurring gains and losses is expected to be 164 million yuan, a 2,174.55% increase year-on-year; basic earnings per share are projected to be 0.2697 yuan per share. In the same period last year, the company achieved a net profit attributable to shareholders of 15.2 million yuan, with a net profit after deducting non-recurring gains and losses of -7.9 million yuan, and basic earnings per share of 0.0249 yuan.

The announcement states that the main reasons for the performance change include the company’s initial success in transforming from a generic drug company to an innovative drug development strategy, with positive progress in business expansion during the reporting period, bringing new growth points, and continued increased investment in R&D; at the same time, the company strengthened internal management, increased efforts to recover accounts receivable, and effectively accelerated cash flow recovery.